Introduction
============

Management of chronic disease often involves long-term and potentially life-long pharmacologic interventions. In a variety of disease states, adherence to treatment, defined as taking medication at the prescribed dose and schedule, is important because poor adherence results in suboptimal outcomes including disease progression, the development of resistance, greater disability, acute and more intense relapses, and premature death.[@b1-ceor-6-197]--[@b4-ceor-6-197] No standard methodology for assessing adherence to prescribed medication exists, and measuring adherence can be challenging.[@b5-ceor-6-197],[@b6-ceor-6-197] Direct methods, which include blood and urine drug assays, drug markers, and direct observation of the patient taking the medication, are laborious, costly, and time intensive, and are generally reserved for clinical trials.[@b5-ceor-6-197],[@b6-ceor-6-197] In real-world settings, the most common measures of adherence include patient self-report, prescription claims databases, electronic monitoring, and pill counts, each with their own advantages and limitations.[@b5-ceor-6-197] The use of administrative claims databases offers the advantage of utilizing large sample sizes to assess adherence.[@b7-ceor-6-197]

One common measure of adherence, particularly when working with data from large administrative claims databases, is the proportion of days covered (PDC). PDC is defined as the number of days covered by medication in the follow-up period divided by the total number of days during follow-up, multiplied by 100 to yield a percentage from 0%--100%.[@b8-ceor-6-197]--[@b10-ceor-6-197] Although useful in drawing simple conclusions, PDC is limited in that it does not distinguish between different patterns of adherence. For instance, some patients may initially be adherent, but then become less adherent as time progresses. Some patients may be adherent in an "off-and-on" pattern, while others may start off with poor adherence and then become more adherent. Thus, it is likely that a similar PDC could be calculated for patients who demonstrate very different adherence patterns. For example, a PDC of 50% could be calculated for a patient who takes their medication for 10 days on and 10 days off continuously during a given year; however, this same PDC would be generated for a patient who takes their medication for 6 months straight, and then not at all for the remainder of the year.

Group-based trajectory model (GBTM) has been proposed as a way to overcome this limitation.[@b11-ceor-6-197],[@b12-ceor-6-197] GBTM is used to describe different developmental trajectories of an outcome over time, and it identifies clusters of individuals who, on the basis of some prespecified biological, behavioral, or physical outcome measure, follow similar longitudinal patterns.[@b11-ceor-6-197] This methodology has been extensively applied in psychology, medicine, and criminology,[@b11-ceor-6-197],[@b12-ceor-6-197] but few studies have investigated adherence using GBTM.[@b13-ceor-6-197],[@b14-ceor-6-197] In one study, adherence to airway clearance therapy in patients with cystic fibrosis was analyzed by GBTM.[@b13-ceor-6-197] This secondary data analysis of a randomized clinical trial identified three adherence trajectories in relation to airway clearance therapy, with those patients demonstrating initial "high" or "low" adherence remaining consistent across the follow-up, and those demonstrating "medium" adherence showing the most variability in adherence to therapy. In a second study, GBTM was used to assess adherence to statin therapy from a prescription claims database over a 15-month time period.[@b14-ceor-6-197] A four-group trajectory model was found to forecast long-term adherence more effectively than PDC, although the accuracy of identifying predictors of adherence was similar for both methods.

In all disease states, it is important to understand adherence and the factors that influence it, as the effectiveness of any drug is dependent on patient adherence, and poor adherence may result in poor clinical and economic outcomes.[@b4-ceor-6-197],[@b15-ceor-6-197],[@b16-ceor-6-197] For example, in an analysis of adherence to statin therapy in newly treated patients tracked in an administrative database, compared with a PDC \>80%, a PDC of 21%--40% was associated with a greater risk of all-cause death, acute myocardial infarction, and stroke.[@b16-ceor-6-197] Given the importance of adherence, the current study applies GBTM to assess biologic use in patients with psoriasis. Specifically, the primary objective of this study compares GBTM and PDC by grouping patients on the basis of drug utilization for 12 months after starting treatment with a biologic and presents researchers with a more accurate method to examine drug adherence. A second objective was to identify the clinical and demographic factors associated with different GBTM-based adherence groups.

Materials and methods
=====================

Data sources
------------

This retrospective cohort study used data from the Truven Health MarketScan^®^ Commercial Claims and Encounter and the Medicare Supplemental and Coordination of Benefits databases. These databases track information from several million people who are enrolled in commercial health insurance plans sponsored by more than 300 employers in the United States. Available data include monthly enrollment figures, hospitalization and outpatient medical claims, outpatient prescription drug claims, and eligibility information.[@b17-ceor-6-197] These databases allow medical claims to be linked to outpatient prescription drug claims and person-level enrollment data through the use of unique patient identifiers, and they provide detailed cost (payment) and health care utilization information for health care services performed in both inpatient and outpatient settings, in addition to standard demographic variables (ie, age, sex, employment status, geographic location). All study data were accessed using techniques compliant with the Health Insurance Portability and Accountability Act of 1996, and no identifiable protected health information was used in the conduct of this study; therefore, informed consent or institutional review board approval was not required.[@b17-ceor-6-197]

Patient cohort
--------------

Patients from the selected databases were included in these analyses if they had at least one confirmed diagnosis of psoriasis, identified by the International Classification of Diseases, Ninth Revision, Clinical Modification code of 696.1x,[@b18-ceor-6-197] and had been prescribed at least one biologic between January 1, 2007 and June 30, 2011. Eligible biologics included etanercept (Immunex Corporation, Thousand Oaks, CA, USA), adalimumab (AbbVie Inc., North Chicago, IL, USA), ustekinumab (Janssen Biotech, Inc., Horsham, PA, USA), and infliximab (Janssen Biotech, Inc.). Patients were excluded if they had a diagnosis of psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, or Crohn's disease, because the presence of these diseases might influence medication adherence patterns. For each patient, the index date was the date of the first use of the biologic agent between January 1, 2008 and June 30, 2010. At baseline, eligible patients were required to have had at least 12 months of database-documented continuous medical and pharmacy claims coverage prior to the index date to help ensure there was no biological use in the preceding 12 months (ie, that selected patients were "new to treatment"). In addition, eligible subjects had to have had at least 12 months of continuous medical and pharmacy coverage after the index date (ie, during follow-up), in order to allow complete observation of adherence during the follow-up period. Patients were excluded from these analyses if they were younger than 18 years old, received any biologic billed with a J-code (these biologics did not have day of supply information in the database), used any biologic (etanercept, adalimumab, ustekinumab, infliximab) in the previous 12 months prior to the index date, or had missing data related to age, sex, region, or health plan type.

Measuring biologic use
----------------------

Prescribing information (PI) for the use of biologics for psoriasis mandates different treatment intervals (ie, a different length of time between each injection) for each brand of biologic: for example, patients who use etanercept are prescribed an injection once a week, whereas patients treated with ustekinumab are prescribed one injection every 3 months during the maintenance period. Because of prescribing differences like this, patients in these analyses were administered different biologics on different treatment schedules, requiring standardization of these divergently timed injections. Thus, on the basis of recommended timing for each drug's injections in their PIs, each injection of a particular biologic was coded as either a 1-week or a multiple-week event, and each single injection was considered to "cover" a period of time determined by when the next injection was recommended. Specifically, if the PI required weekly treatment for a given biologic, a patient was considered to be "on" the treatment for one week following each given injection of that biologic; if the PI required one injection every 3 months, the patient was considered to be "on" that biologic for the next 13 weeks (91 days) for each given injection of that biologic.

The 12-month follow-up period for each patient was converted into 52 weekly observation intervals starting from the index date, and the status of biologic use in each interval was determined on the basis of observed biologic use and the strategy noted above. Because the actual injection of a biologic might be provided on any given day in each observation interval, the patient was considered to be "on" the treatment in each interval if 4 days of the 7 days in that interval were covered by the patient's biologic. Using this schema, all 52 treatment intervals were assessed and coded, with 1 indicating the use of the prescribed biologic during that interval, and 0 denoting no use during that interval.

Adherence group classification based on GBTM
--------------------------------------------

In GBTM, individuals who experience or follow a similar longitudinal progression of some outcome or behavior are identified and "clustered" together.[@b19-ceor-6-197] The complete methodology has been described previously.[@b11-ceor-6-197],[@b12-ceor-6-197],[@b19-ceor-6-197],[@b20-ceor-6-197] Briefly, GBTM assumes that there are unobserved subpopulations or distinct groups based on their developmental trajectory over time. The probability of belonging to one of these groups can be estimated for each individual, and the unknown distribution of trajectories across subpopulations can be approximated. Statistically, GBTM involves the simultaneous estimation of several regression models, combining the information from all models to determine the maximum likelihood of belonging to a potential trajectory group for the same person.[@b11-ceor-6-197] In our current model, a binary trajectory model was repeated with group options from 2 through 6 using the built-in function of the "Proc Traj" add-on package (<http://www.andrew.cmu.edu/user/bjones/index.htm>) for SAS-based analyses (version 9.3; SAS Institute Inc., Cary, NC, USA). Group options represented the different potential trajectory paths. The optimal group model was selected by the balance between the Bayesian information criterion (BIC) value,[@b21-ceor-6-197]--[@b23-ceor-6-197] and the proportion of estimated trajectory groups (ie, at least 0.05, meaning that the smallest group includes at least 5% of patients).[@b11-ceor-6-197] In this study, adherence to biologic treatment over a 12-month period was evaluated using GBTM. Each patient was assessed and assigned to one and only one trajectory group.

Comparison of PDC measures with GBTM measures in patient grouping
-----------------------------------------------------------------

In most adherence studies, PDC is a static measure of patient adherence during follow-up.[@b8-ceor-6-197],[@b9-ceor-6-197],[@b24-ceor-6-197] In application, researchers divide a cohort of patients into groups on the basis of their PDC. For example, patients may be categorized on the basis of quartile divisions of PDC. In order to understand the similarities or differences in patient classification based upon these two methods, a number of groups comparable to the number of groups generated by GBTM were generated from the same patient data based on the PDC method. These groupings were used to 1) compare patient distributions across the two different methodologies (GBTM and PDC) and 2) assess "within group" variance for each PDC-based or GBTM-based group. This "within group" variance was a gauge of homogeneity within each group, with smaller variance scores indicating a more homogeneous patient group (refer to [Figure S1](#SD1-ceor-6-197){ref-type="supplementary-material"} for the detailed formula). The "within-group" variance for corresponding groups from the PDC-based and GBTM-based analyses was directly compared.

Variables associated with likelihood of different trajectory groups
-------------------------------------------------------------------

Using trajectory classifications from the optimal GBTM model, patient demographics, clinical characteristics, and treatment characteristics were summarized for the patients in each GBTM group and subjected to further analyses in order to profile patients in each GBTM group. In addition, a multinomial logistic regression model was used to understand the relationship between these characteristics and the likelihood of being a member of different trajectory groups. The dependent variable was defined as each patient's treatment group as revealed by GBTM, while independent variables included patient age; sex; insurance plan type; region; initial biologic used in index date; oral, topical, or phototherapy use; and nonpsoriasis-related and psoriasis-related comorbidities during the 12-month follow-up period (as listed in [Table S1](#SD3-ceor-6-197){ref-type="supplementary-material"}).

Results
=======

Final patient sample
--------------------

A total of 21,168 patients with psoriasis and prescribed at least one biologic were identified in the selected databases during the defined study period. After applying the exclusion criteria, a total of 3,366 patients remained eligible for the study. However, relatively few of these patients were prescribed either infliximab or ustekinumab, and ultimately, patients initiating biologic treatment with either of these two therapies were excluded from the analyses. As a result, final analyses include 3,249 patients; all of whom received either etanercept or adalimumab.

Group-based trajectory modeling of adherence
--------------------------------------------

The GBTM was performed with models ranging from two to six groups, with time as the only covariate, in order to determine an optimal model ([Table 1](#t1-ceor-6-197){ref-type="table"}). Although lower BIC values, which are an indicator of a better model fit, were obtained with increasing number of groups, the size of the smallest group in all models of five or more trajectory groups was deemed insufficient for further analysis. For example, compared with Model 4 (a five-group model), Model 3 (a four-group model) demonstrated a relatively negligible BIC difference of 2%, but 15.7% of patients were uniquely classified in the smallest subgroup in the four-group model, whereas in Model 4 (the five-group model) only 5.8% of patients were classified into the smallest subgroup. On the basis of the pattern of results and the balancing of BIC values and subgroup sizes, the four-group model suggested by Model 3 was selected as optimal.

Adherence patterns by trajectory group
--------------------------------------

Based on the adherence curves, adherence in each GBTM-defined subgroup was classified as reflecting continuously high adherence, high-then-low adherence, moderate-then-low adherence, or consistently moderate adherence ([Figure 1](#f1-ceor-6-197){ref-type="fig"}).

Adherence patterns by PDC
-------------------------

Because the optimal GBTM suggested four trajectory groups, four adherence groups were derived from PDC measures for comparison purposes; patients were classified into one of four groups based upon PDC rates of \<25%, 25%--49%, 50%--74%, or ≥75%. Adherence curves, reflecting the mean PDC of each PDC-defined group during each week, were also constructed ([Figure 2](#f2-ceor-6-197){ref-type="fig"}).

Comparison of adherence patterns on the basis of methodology
------------------------------------------------------------

Based upon [Figures 1](#f1-ceor-6-197){ref-type="fig"} and [2](#f2-ceor-6-197){ref-type="fig"}, when comparing GBTM-defined and PDC-defined classification of patients into groups defined by adherence level, no meaningful differences are evident in terms of longitudinal adherence patterns for patients with either very good or very poor adherence to their biological therapy. However, for patients categorized as exhibiting medium levels of adherence, different longitudinal patterns are evident depending on the classification model used (PDC versus GBTM).

The majority of patients (97.9%) from PDC Group 2 (PDC \<25%) were patients with moderate-then-low adherence, and the majority (96.4%) of those from PDC Group 4 (PDC ≥75%) were patients who had continuously high adherence ([Table 2](#t2-ceor-6-197){ref-type="table"}). The other two PDC-defined adherence groups showed more variable patterns of adherence based upon GBTM trajectories: 25.3%, 17.2%, and 57.5% patients from PDC Group 3 (25%≤ PDC \<50%) were patients with consistently moderate adherence, moderate-then-low adherence, and high-then-low adherence, respectively, and 70.8%, 23.6%, and 5.7% from PDC Group 1 (50%≤ PDC \<75%) were patients with consistently moderate adherence, high-then-low adherence, and continuously high adherence, respectively.

Demographic, clinical, and treatment profiles for patients in different trajectory groups
-----------------------------------------------------------------------------------------

Patients with consistently moderate adherence had a lower mean age than the other groups ([Table 3](#t3-ceor-6-197){ref-type="table"}). Significantly more patients with continuously high adherence were male, and significantly more patients with consistently moderate adherence were female. Fewer patients who had continuously high adherence lived in the south and more of these patients lived in the north central region. The use of concomitant topical, oral, or photo therapy was different across the various trajectory-defined groups. Overall, the use of any concomitant therapy was greatest for patients who had moderate-then-low adherence and those with high-then-low adherence. Patients with moderate-then-low adherence were significantly more likely to have a nonpsoriasis-related comorbidity than were the other adherence groups. Patients with moderate-then-low adherence were also more likely to have the psoriasis-related comorbidity of peripheral vascular disease/cerebrovascular disease/coronary heart disease.

Prediction of GBTM-based adherence group from other variables
-------------------------------------------------------------

Mean age had the greatest influence on adherence, with younger patients significantly more likely to exhibit any adherence pattern other than continuously high adherence ([Table 4](#t4-ceor-6-197){ref-type="table"}). Males were significantly more likely than females to show either moderate-then-low adherence or high-then-low adherence, but were not more likely to exhibit consistently moderate adherence compared with those with continuously high adherence. Oral or topical psoriasis drug use during the 12-month follow-up was associated with less adherence to biologic therapy, with such concomitant therapy significantly associated with both moderate-then-low adherence and high-then-low adherence. Finally, compared to those without comorbid anxiety, those with comorbid anxiety during follow-up had significantly greater odds of exhibiting either moderate-then-low or high-then-low patterns of adherence.

Within-group variance in each adherence group: GBTM-defined versus PDC-defined
------------------------------------------------------------------------------

Finally, the within-group variance in each GBTM-defined and PDC-defined adherence subgroup was calculated; corresponding groups from each analytic method were compared ([Figure S2](#SD1-ceor-6-197){ref-type="supplementary-material"}). In general, the within-group variance rate did not statistically differ when comparing each GBTM-based subgroup with its corresponding PDC-defined group. However, for the pair of adherence subgroups defined by GBTM as high-then-low adherence and defined by PDC as 25%≤ PDC \<50%, a significant difference emerged: the within-group variance in the GBTM-defined group was much smaller than that from the PDC-defined subgroup, implying that patients in the GBTM-defined high-then-low adherence group showed less variability in longitudinal adherence patterns than did the patients in the group defined as 25%≤ PDC \<50%.

Discussion
==========

The current study applied GBTM to detect and define group-level adherence patterns in a cohort of patients during the 12 months following initiation of a biologic treatment for their psoriasis. Each patient, who had been identified from the large medical and pharmacy claim database, was uniquely classified into one adherence-defined trajectory group, as well as one of four quartile-defined groups determined by PDC. The classifications suggested by GBTM and by PDC were compared with each other by examining the distribution of patients derived from both methods, as well as by directly comparing the within-group variance seen in each pair of defined groups, one based on GBTM and the other from PDC. In addition, the patient profiles in each GBTM-defined trajectory group were described, and baseline demographic and clinical characteristics, as well as the presence of comorbid conditions or concomitant psoriasis treatment during follow-up, were statistically compared across each GBTM-defined group. Finally, the ability of patient demographic, clinical, and treatment characteristics to predict GBTM-defined adherence patterns were established using a multinomial logistic regression model.

In these large, cohort-based analyses, the potential utility of GBTM in understanding the adherence of psoriasis patients initiating biological therapy was suggested by the adherence patterns produced by GBTM-based analyses contrasted with those based on PDC. The use of GBTM modeling allows the classification of unknown longitudinal patterns of adherence across population members and, compared to a more static adherence measure such as PDC, leads to the creation of adherence group classifications with increased homogeneity. GBTM-based models may be especially important for groups that display more variation in adherence over time, such as those in this study who had consistently moderate adherence or high-then-low adherence. The true pattern of adherence seen in these groups was not readily visible with a traditional adherence measure, such as PDC. Of course, for patients who displayed the most consistent adherence patterns over time, both GBTM-based and PDC-based analyses seemed to enable equally informative and similar classifications. As would be expected, the consistency between the GBTM and PDC models was greater for the two groups that were the most consistent over time: those with continuously high adherence and PDC Group 4 (PDC ≥75%) or those with moderate-then-low adherence and PDC Group 2 (PDC \<25%).

One of the goals of health economics and outcomes research is to classify patients into groups with similar treatment patterns, such as those determined by adherence rates, enabling meaningful comparisons on important outcome variables to be made.[@b25-ceor-6-197] Greater homogeneity among similarly classified patients on the metric that defines their classification, such as adherence, should enable more precise evaluation of the relationship between that metric and outcomes, and minimize noise. In this study, we compared "within-group" variance between roughly equivalent GBTM-based and PDC-defined adherence groups, as a measure of relative homogeneity of adherence within each group. The use of GBTM led to adherence-defined classifications that were more homogeneous than similar classifications suggested by PDC.

One important rationale for using GBTM in the context of population-based adherence studies is to better identify patient and disease characteristics that may predict greater or lesser adherence. Although adherence with biological therapy is generally better than adherence to topical therapy in psoriasis,[@b26-ceor-6-197] it is far from complete, and little is known about what influences adherence to biologic therapy in psoriasis.[@b15-ceor-6-197],[@b27-ceor-6-197] Ultimately, in this study, certain demographic and disease characteristics such as age were more or less associated with adherence in the patients receiving biologic therapy for psoriasis. For example, younger patients and male patients were less likely to be in the "consistently adherent" trajectory group. Interestingly, younger age and being male, among other factors, were also associated with less adherence to topical therapy in a recent systematic review.[@b28-ceor-6-197] It should be noted that, given the size of the sample in our study, some statistically significant associations reported may have limited clinical significance. Given that and the secondary nature of our post-hoc analyses between groups, the clinical relevance of these predictive relationships remains to be defined in future studies, and our results should best be considered as hypotheses for further testing. A better understanding of those identifiable factors that put patients at heightened risk for poorer adherence, across topical, biological, and other therapies, should help identify those patients most at need for greater education, support, or incentives in order to remain adherent.

A limitation of the current study was that only patients who had 12 months of continued enrollment were included, which may have biased the population towards patients who were more adherent or who shared certain unmeasured characteristics, such as overall concern for their health, that impacted adherence. In addition, while claims data identifies patients who fill their prescriptions, it cannot be used to determine whether the patients actually took the medication. This may be especially pertinent early in the follow-up period, since motivation to fill an initial prescription is greater than for subsequent prescriptions.[@b29-ceor-6-197] The results reported here also do not take into account outcomes when assessing adherence. Patients whose adherence was initially good but then dropped off could represent a group of patients whose symptoms improved to the point of not needing ongoing therapy. Conversely, if symptoms significantly worsened, patients may have stopped taking their medication because of perceived ineffectiveness and not as the result of any baseline or disease characteristic, complicating the analysis of predictors of adherence. Finally, this study assessed the use of biologics, all requiring injections. Patients who are treated with injectable drugs may likely have different disease characteristics and may be prone to different patterns of adherence, compared with patients who use oral or inhaled medications. Caution must be applied before conclusions from this study are more widely generalized to the population of psoriatic patients as a whole.

Conclusion
==========

This study helps to illustrate that patient adherence is not always a simple phenomenon, nor is it necessarily consistent over time. Thus, identifying longitudinal and potentially dynamic patterns of adherence using GBTM may result in more useful classifications than would using a more traditional measure such as PDC. Through the application of GBTM in a large population of patients initiating biologic therapy for their psoriasis, four adherence trajectories were identified: continuously high adherence, high-then-low adherence, moderate-then-low adherence, and consistently moderate adherence. Recognizing these patterns of adherence may enable more nuanced, more sophisticated, and less error-prone study within this population, compared with categorizing patients by levels of a static, predetermined, threshold measure such as PDC. GBTM offers researchers an alternative method of determining adherence to treatment, one that better captures dynamic changes in adherence over time. By more accurately modeling adherence patterns, the factors that influence adherence may be more clearly elucidated.

Supplementary material
======================

###### 

Calculation of within-group variance.

**Notes:** Step 1: Within each group, calculate variance at each time point *k*. Step 2: Now, we have 52 observations for each trajectory group and 52 observations for each PDC group. Then apply 2-sample Student's *t*-test for Trajectory Group *i* versus PDC Group *i*. Before 2-sample Student's *t*-test, *F*-test for testing equal variance is performed. Select 2-sample Student's *t*-test with equal variance or 2-sample Student's *t*-test with unequal variance based on the result of the *F*-test. Under the assumption of equal variances, the pooled estimate of the common standard error is calculated. Under the assumption of unequal variances (the Behrens--Fisher problem), the unpooled standard error is computed and degrees of freedom are calculated by using Satterthwaite's approximation.

**Abbreviation:** PDC, proportion of days covered.

###### 

Comparison of "within group" variance from GBTM and from PDC measure.

**Note:** Difference is PDC -- GBTM.

**Abbreviations:** GBTM, group-based trajectory model; PDC, proportion of days covered.

###### 

Patient comorbidities

  Comorbidities                                                                                                                      ICD-9-CM code
  ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  Psoriasis-related comorbidities                                                                                                    
   Dementia                                                                                                                          290, 331.0, 331.1, 331.2
   Chronic pulmonary disease                                                                                                         415.0, 416.8, 416.9, 491--494, 496
   Liver disease                                                                                                                     571.2, 571.5, 571.6, 571.8, 571.9, 572.2, 572.3, 572.4, 456.0, 456.1, 456.2
   Renal disease                                                                                                                     585, 586, V420, V451, V56
   Peptic ulcer disease                                                                                                              531--534
   Rheumatologic disease other than rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and Sjögren's syndrome   710.3, 710.4, 710.5, 710.8 and 710.9; excluding 714.0, 710.0, 710.1, 710.2
   Hemiplegia                                                                                                                        342, 344
   Acquired immunodeficiency syndrome                                                                                                042, 043, 044
  Non--psoriasis-related comorbidities                                                                                               
   Type 2 diabetes                                                                                                                   250
   Anxiety                                                                                                                           300.0
   Depression                                                                                                                        296.2, 296.3, 298.0, 300.4, 309.1, 311
   Hypertension                                                                                                                      401--404
   Hyperlipidemia                                                                                                                    272.0--272.4
   Coronary heart disease                                                                                                            410--414
   Cerebrovascular disease (stroke)                                                                                                  430--438
   Peripheral vascular disease                                                                                                       440, 441, 443, 447.1, 557.1, 557.9, V43.4
   Obesity                                                                                                                           278.0
   Rheumatoid arthritis                                                                                                              714.0
   Crohn's disease or ulcerative colitis                                                                                             555--556
   Multiple sclerosis                                                                                                                340
   Other autoimmune disorders: alopecia areata                                                                                       704.01
   Celiac disease                                                                                                                    579.0
   Systemic sclerosis                                                                                                                710.1
   Sjögren's syndrome                                                                                                                710.2
   Vitiligo                                                                                                                          709.01, 374.53
   Chronic urticaria                                                                                                                 708
   Systemic lupus erythematosus                                                                                                      710.0
   Addison's disease                                                                                                                 255.4
   Giant cell arteritis                                                                                                              446.5
   Pulmonary fibrosis                                                                                                                515, 516.31
   Chronic glomerulonephritis                                                                                                        582
   Skin cancer                                                                                                                       Melanoma skin cancer 172; non-melanoma skin cancer 173
   Lymphoma                                                                                                                          Non-Hodgkin's lymphomas, ICD-9 codes: 200.0--200.7, 202.1, 202.2, 202.7; Hodgkin lymphoma, ICD-9 codes: 201.0--201.9
   Other malignancies                                                                                                                Cancers of lung, pharynx, liver, pancreas, breast, vulva, penis, bladder, and kidney: 162, 146, 155, 157, 174, 184.4, 187, 156, 189, respectively

**Abbreviation:** ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical Modification.
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![Adherence curves from GBTM: trend by trajectory group.\
**Note:** Compliance reflects percentage of patients "on" prescribed therapy during each week (ie, each 7-day treatment interval).\
**Abbreviation:** GBTM, group-based trajectory model.](ceor-6-197Fig1){#f1-ceor-6-197}

![Adherence curves and trend from PDC group.\
**Note:** Compliance reflects mean PDC of each PDC-defined group during each week (ie, each 7-day treatment interval).\
**Abbreviation:** PDC, proportion of days covered.](ceor-6-197Fig2){#f2-ceor-6-197}

###### 

BIC values and predicted group proportions from GBTM

  Model ID   Groups, n   BIC      Patients in each predicted group (%)                                      
  ---------- ----------- -------- -------------------------------------- ------ ------ ------ ------ ------ ------
  1          2           −79593   37.9                                   62.1   --     --     --     --     --
  2          3           −74016   29.7                                   20.3   50.0   --     --     --     --
  3          4           −70996   23.0                                   19.2   15.7   42.1   --     --     --
  4          5           −69370   21.1                                   5.8    15.9   14.5   42.7   --     --
  5          6           −67692   16.2                                   5.8    12.0   11.8   12.0   42.2   --
  6          7           −66537   20.8                                   11.0   6.0    10.6   8.8    9.8    33.0

**Note:** Shaded row indicates the optimal model (the 4-group model suggested by Model 3) based on the pattern of results and the balancing of BIC values and subgroup sizes.

**Abbreviations:** BIC, Bayesian information criterion; GBTM, group-based trajectory model; n, number; ID, identification.

###### 

Patient distribution from GBTM relative to patient distribution from PDC group

  GBTM Group                        PDC Group 2 (PDC \<25%)   PDC Group 3 (25%≤ PDC \<50%)   PDC Group 1 (50%≤ PDC \<75%)   PDC Group 4 (PDC ≥75%)   Mean of PDC
  --------------------------------- ------------------------- ------------------------------ ------------------------------ ------------------------ -------------
  Moderate-then-low adherence       524 (97.9%)               99 (17.2%)                     0                              0                        17.9%
  Consistently moderate adherence   7 (1.3%)                  145 (25.3%)                    538 (70.8%)                    50 (3.6%)                60.5%
  High-then-low adherence           4 (0.7%)                  330 (57.5%)                    179 (23.6%)                    0                        47.1%
  Continuously high adherence       0                         0                              43 (5.7%)                      1,330 (96.4%)            87.7%
  Total                             535 (100.0%)              574 (100.0%)                   760 (100.0%)                   1,380 (100.0%)           

**Abbreviations:** GBTM, group-based trajectory model; n, number; PDC, proportion of days covered.

###### 

Demographic, clinical, and treatment profiles for patients in different trajectory groups

  Variable                                                     Consistently moderate adherence   Moderate-then-low adherence   High-then-low adherence   Continuously high adherence   *P*-value                             
  ------------------------------------------------------------ --------------------------------- ----------------------------- ------------------------- ----------------------------- ----------- -------- ------- -------- ---------
  Patients, n Baseline                                         740                               100.0%                        623                       100.0%                        513         100.0%   1,373   100.0%   
   Age, years, mean (SD)                                       44.3                              12.9                          47.5                      14.3                          47.2        12.8     48.9    12.7     \<0.001
   Sex, n (%)                                                                                                                                                                                                                \<0.001
    Male                                                       417                               56.4%                         293                       47.0%                         263         51.3%    834     60.7%    
    Female                                                     323                               43.6%                         330                       53.0%                         250         48.7%    539     39.3%    
   Plan type, n (%)                                                                                                                                                                                                          0.012
    FFS                                                        591                               79.9%                         517                       83.0%                         441         86.0%    1,163   84.7%    
    HMO and POS capitation                                     149                               20.1%                         106                       17.0%                         72          14.0%    210     15.3%    
   Region, n (%)                                                                                                                                                                                                             \<0.001
    Northeast                                                  83                                11.2%                         55                        8.8%                          57          11.1%    147     10.7%    
    North central                                              180                               24.3%                         144                       23.1%                         126         24.6%    395     28.8%    
    South                                                      344                               46.5%                         330                       53.0%                         252         49.1%    558     40.6%    
    West                                                       133                               18.0%                         94                        15.1%                         78          15.2%    273     19.9%    
  Follow-up period[a](#tfn4-ceor-6-197){ref-type="table-fn"}                                                                                                                                                                 
   Oral drug use, n (%)                                        42                                5.7%                          96                        15.4%                         70          13.6%    123     9.0%     \<0.001
   Topical drug use, n (%)                                     403                               54.5%                         411                       66.0%                         343         66.9%    810     59.0%    \<0.001
   Phototherapy use, n (%)                                     22                                3.0%                          49                        7.9%                          34          6.6%     60      4.4%     \<0.001
  Non PsO-related comorbidity groups, n (%)                                                                                                                                                                                  
   Any non-PsO related                                         51                                6.9%                          87                        14.0%                         44          8.6%     97      7.1%     \<0.001
   Chronic pulmonary disease                                   38                                5.1%                          58                        9.3%                          34          6.6%     68      5.0%     0.001
   Others                                                      14                                1.9%                          35                        5.6%                          11          2.1%     36      2.6%     \<0.001
  PsO-related comorbidity groups, n (%)                                                                                                                                                                                      
   Any of PsO related                                          337                               45.5%                         333                       53.5%                         272         53.0%    706     51.4%    0.011
   Diabetes                                                    89                                12.0%                         94                        15.1%                         74          14.4%    181     13.2%    0.359
   Anxiety                                                     27                                3.6%                          37                        5.9%                          29          5.7%     38      2.8%     0.002
   Depression                                                  39                                5.3%                          44                        7.1%                          44          8.6%     84      6.1%     0.105
   Hypertension                                                172                               23.2%                         172                       27.6%                         152         29.6%    392     28.6%    0.034
   Hyperlipidemia                                              123                               16.6%                         113                       18.1%                         104         20.3%    286     20.8%    0.097
   PVD/CVD/CHD                                                 31                                4.2%                          63                        10.1%                         44          8.6%     108     7.9%     \<0.001
   Obesity                                                     33                                4.5%                          25                        4.0%                          16          3.1%     51      3.7%     0.660
   Crohn's disease or UC/other autoimmune disorders            17                                2.3%                          14                        2.2%                          14          2.7%     26      1.9%     0.727
   Skin cancer/other malignancies                              13                                1.8%                          24                        3.9%                          12          2.3%     55      4.0%     0.02

**Note:**

The biologics of two brand names were controlled in the model; however, results were not reported due to sensitivity issues related to the comparison between different drugs.

**Abbreviations:** CHD, coronary heart disease; CVD, cerebrovascular disease; FFS, fee for service; HMO, health maintenance organization; n, number of patients; POS, point of service; PsO, psoriasis; PVD, peripheral vascular disease; SD, standard deviation; UC, ulcerative colitis.

###### 

The association of independent variables between the different GBTM groups: results from multinomial logistic regression

                                                      Consistently moderate adherence (n=740)   Moderate-then-low adherence (n=623)   High-then-low adherence (n=513)   Continuously high adherence (n=1,373)                                 
  --------------------------------------------------- ----------------------------------------- ------------------------------------- --------------------------------- --------------------------------------- ------------------- --------- -----------
  **Intercept**                                                                                                                                                                                                                               
  Demographic characteristics                                                                                                                                                                                                                 
   Age                                                0.98 (0.97--0.98)                         \<0.0001                              0.99 (0.98--0.99)                 0.001                                   0.99 (0.98--1.00)   0.002     Reference
   Sex (female versus male)                           1.20 (1.00--1.45)                         0.056                                 1.67 (1.37--2.04)                 \<0.0001                                1.45 (1.18--1.79)   0.001     Reference
   Region (North Central versus Northeast)            0.91 (0.66--1.27)                         0.593                                 1.04 (0.72--1.52)                 0.829                                   0.87 (0.60--1.27)   0.473     Reference
   Region (South versus Northeast)                    1.23 (0.90--1.68)                         0.193                                 1.76 (1.24--2.50)                 0.002                                   1.28 (0.90--1.81)   0.167     Reference
   Region (West versus Northeast)                     0.90 (0.64--1.29)                         0.572                                 0.95 (0.64--1.42)                 0.808                                   0.80 (0.53--1.19)   0.268     Reference
   Plan Type (HMO/POS capitation versus FFS)          1.36 (1.06--1.73)                         0.014                                 1.19 (0.91--1.55)                 0.215                                   0.94 (0.70--1.27)   0.698     Reference
  Comorbidities in follow-up period                                                                                                                                                                                                           
   Diabetes                                           1.23 (0.91--1.65)                         0.173                                 1.24 (0.92--1.67)                 0.161                                   1.21 (0.88--1.66)   0.234     Reference
   Anxiety                                            1.22 (0.73--2.06)                         0.450                                 1.97 (1.20--3.21)                 0.007                                   1.80 (1.08--3.02)   0.025     Reference
   Depression                                         0.78 (0.52--1.18)                         0.237                                 0.95 (0.63--1.42)                 0.796                                   1.25 (0.84--1.86)   0.281     Reference
   Hypertension                                       1.00 (0.79--1.27)                         0.996                                 0.94 (0.74--1.20)                 0.624                                   1.16 (0.90--1.49)   0.248     Reference
   Hyperlipidemia                                     0.95 (0.74--1.23)                         0.712                                 0.81 (0.62--1.06)                 0.124                                   0.96 (0.73--1.27)   0.790     Reference
   PVD/CVD/CHD                                        0.72 (0.46--1.11)                         0.135                                 1.52 (1.05--2.20)                 0.027                                   1.28 (0.86--1.92)   0.223     Reference
   Obesity                                            1.23 (0.77--1.98)                         0.388                                 0.93 (0.56--1.57)                 0.795                                   0.74 (0.41--1.33)   0.310     Reference
   Crohn's disease or UC/other autoimmune disorders   1.37 (0.72--2.60)                         0.336                                 1.13 (0.57--2.25)                 0.724                                   1.50 (0.76--2.96)   0.241     Reference
   Skin cancer/other malignancies                     0.62 (0.33--1.17)                         0.138                                 0.96 (0.57--1.63)                 0.882                                   0.63 (0.33--1.22)   0.172     Reference
   CPD                                                1.37 (0.90--2.11)                         0.146                                 1.97 (1.33--2.91)                 0.001                                   1.39 (0.89--2.17)   0.144     Reference
   Other non PsO-related comorbidities                0.86 (0.45--1.64)                         0.646                                 2.04 (1.23--3.38)                 0.006                                   0.77 (0.38--1.56)   0.468     Reference
  Drug use in follow-up period                                                                                                                                                                                                                
   Oral drug use                                      0.92 (0.84--1.01)                         0.096                                 1.14 (1.07--1.21)                 \<0.0001                                1.09 (1.02--1.17)   0.015     Reference
   Topical drug use                                   0.98 (0.95--1.02)                         0.376                                 1.07 (1.03--1.11)                 \<0.0001                                1.07 (1.03--1.11)   \<0.001   Reference
   Phototherapy                                       0.99 (0.97--1.01)                         0.283                                 1.00 (0.99--1.02)                 0.542                                   0.99 (0.97--1.01)   0.354     Reference

**Abbreviations:** CHD, coronary heart disease; CI, confidence interval; CPD, chronic pulmonary disease; CVD, cerebrovascular disease; FFS, fee for service; HMO, health maintenance organization; POS, point of service; PsO, psoriasis; PVD, peripheral vascular disease; OR, odds ratio; UC, ulcerative colitis; GBTM, group-based trajectory model.
